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Abstract
 This paper examines the financial performance of one of the 2002 worst performing
company, Protein Design Labs Inc. for the period 1993 to 2002. Findings indicate that
the profitability ratios such as return on equity, return on assets and net profit margin
were negative for most of the years between 1993 and 2004. The Pearson’s correlation
coefficient between Protein Design’s net sales and R & D expenditure for the period 1993
to 2004 is .85 and is significant at 1 percent level. Between 1996 and 2004, annual
expenditures on Research and Development exceeded the annual net sales. The current
ratio of Protein Design ranges between 10:1 and 58:1 in 1998 and 2000 respectively.
Protein Design is by far more liquid than its competitors. The Cash flow adequacy and
Cash interest coverage ratios indicate that Protein Design was extremely liquid for most
of the period. Cash flows from financing were responsible for healthy cash flow situation.
The efficiency ratios were poor. They show that during the period, Protein Design had the
lowest total asset turnover when compared to its immediate competitors such as Corixa
and Medummune.  Despite poor earnings generating performance, Protein Design is
among the top emerging pharmaceutical companies attracting high corporate alliances
and investors’ confidence. With a new Chief Executive, a new President of Research and
Development, and a strong balance sheet, Protein Design Labs Inc is expecting greater
profitability in the future.
* Department of Business Administration Eastern Connecticut State University, USA.
  e-mail: nduc@easternct.edu
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I. Introduction
W
hen the Burrill Select Index of Biotechnology firms fell 6% in February
2002, the largest decliner in the group was Protein Design Labs (PDLI)
whose share price declined by  27 percent. This was amidst concerns that Protein
Design’s psoriasis drug, zenapax, might be shown to be ineffective. Zenapax was
currently in Phase II clinical trials whose results are blinded, hence such speculation
may be premature (Burrill & Co, 2002). This drug eventually failed the clinical test
(BTech Investor, 2002).
Protein Design Labs, Inc. is engaged in the discovery and development of humanized
monoclonal antibodies for the treatment of various diseases. The group has licensed
certain rights to first humanized antibody product, zenapax to Hoffmann-la Roche
Inc. and its affiliates, which market it for the prevention of kidney transplant rejection.
Protein Design Labs, Inc. is also testing zenapax for the treatment of auto immune
disease. In addition, the group has several other humanized antibodies in clinical
development for auto immune and inflammatory conditions such as asthma and
cancer. The company is fully integrated from research through clinical development.
The group holds fundamental patents in the United States, Europe and Japan for its
antibody humanization technology. Numerous other pharmaceutical and
biotechnology companies use this technology, many of which have licensed their
patents and have agreed to pay royalties to Protein Design Labs Inc. on any sales
of licensed products.
On April 7th, 2003, the group acquired EOS Biotechnology Inc. Royalties accounted
for 87% of 2002 revenues and license and other, 13%.1 With the above profile,
Protein Design Labs Inc. presents as a company of immense potential. Yet it fared
poorly in the stock market in 2002. Arguably 2002 was a bad year for many
biotechnology, drug and pharmaceutical companies. Its share price between March
and October 2001 ranged between $86.00 and $34.00. In the same period in 2002,
it ranged between $20.00 and $13.00. See Figure 1 below. Prior to 2002, investors
were buying and holding the shares of PDLI. Figure 2 shows the increase in volume
of shares traded.
1 Source: Disclosure’s SEC Database in Thomson Research database, Eastern Connecticut State University.51  No. 217, septiembre-diciembre 2005
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Figure 1
Protein Design Labs Inc. Comparative Share Price 2001 and 2002
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The research objectives of this paper are multiple. First is to use financial and
cash flows statements and any other information available to evaluate the per-
formance of Protein Design Labs Inc. (PDLI), a poorly performing biotechnology
company listed on NASDAQ to determine the reasons for its categorization as
one of the worst performing companies in 2002. Secondly, to highlight the fact
not often contained in Corporate Finance text books that some companies with
poor financial performance can have very strong balance sheet because of
investors’ confidence in their future performance. Such observations should
aid the teaching and conducting of financial evaluations of companies. Another
reason for evaluating a pharmaceutical company, Protein Design Labs Inc.
(PDLI) is because it was rated one of the worst performing companies in 2002
at a time when some drug and pharmaceutical companies were accused of
enjoying supra normal profits and the possibility of price control on prescription
was being discussed.
II. Data and Methodology
Protein Design Labs Inc. (PDLI) consolidated financial statement information
available at the Disclosure SEC Database in the Thomson Research website,
http://0-research.thomsonib.com.csulib.ctstateu.edu/gaportal/ga.asp and Income
Statements, Balance Sheets and Cash flow Statements for the period 1993 to 2002
were used. Supplementary data such as market data were also collected from
Yahoo Finance website, http://finance.yahoo.com/q?s=PDLI.
We examine the profitability, liquidity/solvency, operational efficiency and operating,
investment and financing cash flows of Protein Design Labs Inc. for the period
1993-2004. We also evaluate the justification and relevance of huge expenses
such as research and development expenditure. PDLI’s results were compared
with selected biotechnology major competitors for the years for which data is
available and with the current industry average where necessary.
III. Financial Analysis
This analysis encapsulates time series and cross sectional analysis. The key relevant
profitability, liquidity/solvency, and operational efficiency ratios for the period 1993
to 2004 are contained on Table 1 below.53  No. 217, septiembre-diciembre 2005
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Table 1
Protein Design Labs Inc. Selected Financial Ratios 1993-2004
A. Profitability Analysis
We evaluate the return on equity first using this equation:
Return on Equity (ROE) = Net income after tax ------------------------------(1)
               Common equity
The return on equity (ROE) is considered to be the most important of all ratios.
This is derived from the fundamental objective of the firm, which is to maximize
the shareholders’ wealth. The PDLI’s ROE is negative for the period except
in 2000 and 2001 when it was .1 percent and .4 percent respectively. To ascertain
whether this observation is in accordance with industry norm, we compare the
PDLI ROE with that of its major competitors Corixa Corp. and Medimmune
Inc for the period 1995 to 2002. As can be seen on Figure 3, all the companies
performed poorly with respect to ROE. The ROE of Corixa Corp. and
Medimmune Inc fluctuated more widely.  It was only between 1998 and 2001
and in 2003 that Medimmune achieved a positive ROE and outperformed Protein
Design. Corixa Corp had negative ROE through out the period and deteriorated
in 2004 to -3.7.54
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Figure 3
Comparative ROE: PDLI, CRXA, MEDI, 1995-2004
We used the Mann-Whitney U Test below, to test the equality of the PDLI’s ROE
with that of its major competitors Corixa Corp. and Medimmune Inc for the period
1995 to 2002.
   -----------------------(2)
Where n1 = number of observations for PDLI; n2 = number of observations for
Corixa; R1 = sum of the ranks of observations for PDLI; R2 = sum of the ranks of
observations for Corixa.
We test the hypothesis:
Ho : µ 1 = µ 2 ← null hypothesis: There is no difference between the ROE of PDLI and
Corixa, in particular, both have the same.
Ho : µ 1 ≠µ 2 ←  alternative hypothesis: There is a difference between the ROE of
PDLI and Corixa, in particular, they have different means.
α  = .01 ←   level of significance for testing these hypotheses.
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We repeat this test for PDLI and Medimmune Inc. The results of the U tests
indicate that the difference between the ROE of PDLI and Corixa is not significant
at the 1 percent level, so we accept the Null hypothesis of equality of means.
However the difference between the ROE of PDLI and Medimmune Inc. is
significant at the 1 percent level, so we reject the Null hypothesis and accept the
Alternative hypothesis that the means are not equal.
The degree of debt in the capital structure might distort the interpretation of the
ROE as companies with higher debt ratio might register higher ROE because
interest expenses are tax deductible.  Therefore we also analyze PDLI profitability
using Return on asset (ROA).
Return on assets = Net income after tax --------------------------(3)
       Total assets
The ROA for the three companies for the period 1995-2004 is contained in Figure
4 below.  The ROA performance is very similar to that of the return on equity and
this is because the three companies have very low debt ratios.
Figure 4
Comparative ROA 1995-2004
Figure 4. Comparative ROA 1995-2004
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Table 2 contains the actual calculated data for ROE and ROA for the PDLI and its
immediate competitors CRXA and MEDI.
Table 2
Comparative Returns of PDLI, CRXA, MEDI, 1993-2004
  Return on Assets    Return on Equity  
Years  PDLI  CRXA MEDI  PDLI  CRXA MEDI 
1993 -0.071  NA -0.2160  -0.08  NA -0.25 
1994 -0.043  NA -0.4210  -0.04  NA -0.55 
1995 -0.072  -0.3363 -0.3954  -0.07  -0.40433 -0.52 
1996 -0.11  -0.2731 -0.1802  -0.11  -0.36944 -0.41 
1997 -0.14  -0.0433 -0.2630  -0.14  -0.05218 -1.10 
1998 -0.06 -0.34839 0.1163 -0.06  -0.50531 0.19 
1999 -0.06 -0.59211 0.1440 -0.06  -0.90091 0.17 
2000 0.0009 -1.32287 0.1104 0.001  -1.64095 0.13 
2001 0.004  -0.0004 0.1204  0.004  -0.00053 0.14 
2002 -0.02 -1.05759 -0.5018 -0.03  -1.61536 -0.65 
2003 -0.07 -0.33492 0.0656 -0.29  -1.0366 0.11 
2004 -0.17 -0.39962 0.0015 -0.13  -3.76538 0.00 
Net profit margin indicates management’s ability to operate the business with
sufficient success not only to recover the cost of the merchandise or service, the
expense of operating the business, and the cost of borrowed funds but also to leave
a margin of reasonable compensation to the owners for putting their capital at risk
(Helfert, 2000).
Net Profit margin = Net profit after tax ------------------------------ (4)
       Sales
Protein Design’s net profit margin shown on Table 1 was negative throughout the
period except for 2000 and 2001 when it was marginally positive. The highest
negative result was -2.14 in 1997.57  No. 217, septiembre-diciembre 2005
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Research findings indicate that there is a very close relationship between the
Research and Development (R & D) pharmaceutical companies. Scherer, (2001),
analyzed data on R & D investment and profits at the aggregate industry level
using Pharmaceutical Research and Manufacturers of America (PHRMA) data.
The result of a time series analysis showed that the growth rate of deflated gross
margins was 4.23 percent per year, much lower than the 7.51 percent growth rate
found for R & D outlays.  Secondly the pharmaceutical industry’s gross margins
exhibit long swings around their exponential time trend. Thirdly the result of a
simple Pearson’s correlation between the two time series is 0.92. At two of the
three clear turning points, he finds that the R & D spending series precede reversals
in the gross margins drive changes in R& D spending. With respect to Protein
Design, we use the Pearson’s correlation coefficient to test the relationship between
the net sales and R & D for the period 1993 to 2002. We find that there is a high
positive correlation of .85 and is significant at 1 percent level.
Between 1996 and 2004, the annual expenditures on Research and Development
exceeded the annual net sales. This observation indicates huge investments in R &
Development.
B. Liquidity/solvency
A liquid firm is one that can meet its various short-term and credit obligations.
Current ratio is commonly used to evaluate the debt exposure represented in the
balance sheet.
Current ratio = Current assets ----------------------------------(5)
 Current Liabilities
The current ratio of protein Design can be seen on Table 1 and it ranges between
10:1 and 58:1 in 1998 and 2000 respectively. Most Corporate Finance textbooks
agree that a very common rule of the thumb suggests that a current ratio of 2:1 is
right for most businesses. Why is Protein Design uncommonly liquid in spite of its
poor profit performance?   The total cash, cash equivalents and marketable securities
are $606.4 million, $650.3million, and $661.73 million in 2002, 2001 and 2000.
According to the annual report 2002, these current assets primarily are derived
from an active effort to license rights under their fundamental antibody humanization
patents to developers of antibody based therapeutics (Protein Design, 2002).58
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The resulting fees and royalties from these licenses have led to a growing revenue
stream and, in turn, have reduced their cash burn. They also received upfront fees
for humanizing antibodies for other companies.
Is this situation peculiar to Protein Design or is it an industry norm? According to
the 2003 second Quarter June 30 report, (Multexinvestor, 2003), Protein Design’s
current ratio was 22.43, industry 5.17, sector 2.66 and &P 500 1.81. Compared to
its major competitors Corixa Corp. and Medimmune Inc. for the period 1993 to
2002, the current Protein Design’s current ratio is very high, especially in 1994 and
from 1999 to 2002.  Table 3 below contains the calculate ratios for the period. The
trend is depicted in Figure 5.
Table 3
Comparative Current Ratios (1993-2004)
 
Years PDLI CRXA  MEDI 
    
1993 14 N/A  9 
1994 30 N/A  4 
1995 13  9  4 
1996 15  5  7 
1997 11  16  2 
1998 10  6  4 
1999 18  2  4 
2000 58  3  5 
2001 52  2  3 
2002 42  2  3 
2003 14  3  3 
2004 9  3  2 59  No. 217, septiembre-diciembre 2005
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Figure 5
Comparative Current Ratios 1993-2004
C. Management efficiency
The total asset turnover is one of the key ratios used to determine how efficiently
a firm has used its assets in generating sales, which is a major determinant of
operating income (Keown, Martin, Petty and Scott, 2003). This is a good indication
of the effectiveness with which management has employed the assets entrusted to
it by the shareholders. To calculate the total asset turnover for Protein Design and
its competitors, we use the formula:
Total asset turnover = Sales   -----------------------------(6)
                            Total assets
Table 4 below shows the total asset turnover for Protein Design Labs Inc. and its
major competitors Corixa Corp. and Medimmune Inc. for the period 1995 to 2004.
Figure 6 below depicts the trend. It shows that during the period, Protein Design
had the lowest total asset turnover. It generated $0.095 in sales per dollar of assets
whereas Corixa generated $0.2 and Medimmune $0.42. Protein Design’s major
competitors seem to be performing poorly too. During the quarter ended on June
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31st 2003, Protein Design’s total asset turnover was $0.09; Biotechnology and
Drugs industry average, $0.67; healthcare sector$0 .81 and S & P 500, $0.92.  The
results of the U test indicate that these differences are not significant even at the
1 percent level.
Table 4
Total Asset Turnover 1995-2004
 
Year PDLI CRXA  MEDI 
      
1995  0.1 0.22 0.48 
1996 0.15  0.38  0.25 
1997 0.06  0.23  0.46 
1998 0.12  0.3  0.45 
1999 0.15  0.29  0.55 
2000 0.06  0.07  0.49 
2001 0.06  0.16  0.47 
2002 0.06  0.25  0.36 
2003 0.90  0.14  0.38 
2004 0.13  0.13  0.44 
Figure 6
Comparative Total Assets Turnover Ratios: PDLI, CRXA and MEDI  1995-2004
Figure 6. Comparative Total Assets Turnover Ratios: PDLI, CRXA and MEDI 
1995-2004.
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Source: Thomson Research website,
http://0-research.thomsonib.com.csulib.ctstateu.edu/gaportal/ga.asp
Although Cash Flow statement (CFS) and its predecessor funds statement has
been around for more than two decades, very few articles in the professional and
academic journals have attempted to develop ratios based on CFS (Bhandari, 2003).
A major problem in using cash flow based ratios for analyzing companies currently
not making profit is that most of them focus on cash flow from operations (Carslaw
& Mills, 1991; Dennis, 1994; Giacomino & Mielke 1988; Mills & Yamamura, 1998;
Siegel & Akel, 1989; Zeller & Stanko, 1994). In evaluating the cash adequacy of
companies with poor earnings, emphasis should be placed on the firm’s ability to
raise funds either through equity issue or through issue of long-term debt securities.
The investors’ (creditors and shareholders) confidence in the present operational
activities and future potentials is demonstrated in their willingness to invest in the
continued operations of such companies. The purpose of cash flow analysis of a
Table 5. Comparative Cash Flow in ($millions), 1993-2004 
                  
  Net Cash Flow from  Net Cash Flow from  Net Cash Flow from  Cash at Year end   
  Operations    Investing    Financing       
Years  PDLI CRXA MEDI PDLI CRXA MEDI PDLI CRXA MEDI PDLI  CRXA  MEDI 
1993  -5.4  NA  -17.5  -23.2  NA 18 30 NA  19.5 6  NA 22.2 
1994  -1.9  NA  -20.3  -44.6  NA 4.1 46 NA  -0.1 5.4 NA 6.4 
1995 -7.1 -3.4 -15.9 -4.8  3.9  -8.4  1.5  48  32.2  4.7  3  14.2 
1996 -7  -2.8  -25.8  -11.8  -2.7 -0.1 4.7  4.7  125.4  14.1  2.1  12.6 
1997 -7.6 -0.3 -54.4  -72.1 -30.9 42.8 74.9 45.6 42.7  9.3  16.5  56.6 
1998 -6.5 -7.5  5.1 21.2 -8.5 -97.8 3.9  8.7  81.1 27.9  91  44.7 
1999 -10.7  -5.7  59  -24.9 -16.4 -120.7 24.9  13.8  54  17.1  0.8  36.7 
2000  6.8  -23.7 173.3  -118.2 -30.7 -195.6 515.9 100.7  74.8  421.5  47.1  85 
2001 2.7 -65.8  250.9  -286.3  50.1  -188.2  -17.5 1.9  23.6  120.3 33.3 171.2 
2002  -5.1 -45 263.5  168.9 9.5 -347 3.8 49.5  42 287.7 47.4 130.1 
2003 -23.6  -53  357.5 -20.9 -92.9 -238.3 98.6 134.9 266.2 341.8  36.9  515.5 
2004 -27.2  -591.4  144.7  240.2 30.3 -300.9  17  10.5 -187.9 91.4  18.6  171.3 
D. Operations, Investments and financing cash flows
Table 5 contains the net cash flow from operations, investments and financing and
cash at end of period in millions of dollars for PDLI and its competitors CRXA and
MEDI. Only MEDI had significant cash flow from operations since 1998. While
net cash flow from investing was generally negative for all the companies, net
cash flow from financing was generally positive for all the companies. It is important
to note that all the companies had significant cash balances at year end
Table 5
Comparative Cash Flow in ($millions), 1993-200462
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firm that is not making profit is to determine its cash availability for continued
operational activities. Therefore cash at closing rather than net operational cash
flow is a better yardstick. In an attempt to remedy this defect, the following key
cash flow ratios are suggested for companies in this situation.
Cash flow adequacy =  Cash at year end  ----------------------(7)
                                       Total debt
Cash interest coverage =   Cash at year end ------------------------(8)
                                     Total Interest expense
IV. Summary of Findings
1. The profitability ratios such as return on equity, return on assets and net profit
margin were negative for most of the years between 1993 and 2002. The U test
results indicate that the difference between the ROE of PDLI and a major
competitor Medimmune Inc. is significant at the 1 percent level. How ever the
difference in ROE for PDLI and another major competitor was not significant
at any level.
2. The Pearson’s correlation coefficient between Protein Design’s net sales and R
& D expenditure for the period 1993 to 2002 is .85 and is significant at 1 percent
level. Between 1996 and 2002, the annual expenditures on Research and
Development exceeded the annual net sales.
3. The current ratio of Protein Design ranges between 10:1 and 58:1 in 1998 and
2000 respectively. Protein Design is by far more liquid than its competitors.
4. The efficiency ratios were poor. They show that during the period, Protein
Design had the lowest total asset turnover. It generated $0.095 in sales per
dollar of assets whereas Corixa generated $0.2 and Medimmune $0.42. However
the results of the U tests indicate that these differences were not significant
even at the 1 percent level.
5. Cash flow adequacy and cash interest coverage ratios indicate that Protein
Design was extremely liquid for most of the period. Cash flows from financing
were responsible for healthy cash flow situation.63  No. 217, septiembre-diciembre 2005
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V. Conclusion
Protein Design Inc. has invested heavily in Research and Development but has
not succeeded in its present research ventures. According to (BTech Investor,
2002) Protein Design Labs’ (NASDAQ: PDLI) phase II investigations of Zenapax
(daclizumab) have failed to meet their primary therapeutic goal in the treatment
of patients with moderate-to-severe psoriasis. Following treatment with the
immunosuppressant cyclosporine, administration of Zenapax did not prolong the
time to recurrence of psoriasis. These developments do not do the future prospects
of Protein Design Inc. justice. The poor profitability efficiency ratios support
this. Yet PDLI has continued to maintain a strong balance as evidenced in the
very current ration, cash flow adequacy and cash interest coverage ratios. To
understand this seemingly diabolical situation, the scale of Protein Design’s
corporate alliances must be taken into account. First rate emerging biotech
companies such as Millennium Pharmaceuticals (MLNM), Human Genome
Sciences (HGSI), Protein Design Labs (PDLI) and Vertex Pharmaceuticals
(VRTX) all boast of partnerships with major pharmaceutical firms involving
payments ranging between $300 million and $800 million. This is scientific validation
by experts, backed up by the steady infusion of cash. Protein Design, in addition
to heavy investment in Research and Development, corporate alliances with major
pharmaceutical firms, engaged on management reorganization. With a new Chief
Executive, a new President of Research and Development, and a strong balance
sheet, Protein Design Labs Inc is expecting greater profitability in the future. In
teaching Corporate Financial Analysis, situations like this must be highlighted and
explained.
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